Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions

Toxicology

Volumn 245, Issue 1-2, 2008, Pages 49-64

  Balakumar, Pitchai ^a   Kaur, Tajpreet ^b   Singh, Manjeet ^a  

^a ISF Institute of Pharmaceutical Sciences and Drug Research   (India)

^b PUNJABI UNIVERSITY   (India)

Author keywords

Cardiovascular disorders; Novel target sites; Vascular endothelial dysfunction

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 AMINOBENZAMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID DIETHYL ESTER; 8 BROMO CYCLIC AMP; ANGIOTENSIN CONVERTING ENZYME 2; BENFOTIAMINE; CAVEOLIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DAIDZEIN; EPOXIDE HYDROLASE; ESTRADIOL; FASUDIL; FIBRIC ACID DERIVATIVE; FINGOLIMOD; GGTI 298; GW 07242; INO 1001; JANUS KINASE; LIPOPROTEIN LIPASE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NORASTERRIQUINONE B1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RHO KINASE; SPHINGOSINE 1 PHOSPHATE; TORCETRAPIB; TRANSKETOLASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROSIS; BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG ACTIVITY; DRUG BINDING; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GLYCATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROKE; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; OXIDATIVE STRESS; RISK FACTORS; VASCULAR DISEASES;

EID: 39249083879     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2007.12.011     Document Type: Review

References (228)

1. Ananthakrishnan R., Hallam K., Li Q., and Ramasamy R. JAK-STAT pathway in cardiac ischemic stress. Vascul. Pharmacol. 43 (2005) 353-356
2. Aoki N., Ueno S., Mano H., Yamasaki S., Shiota M., Miyazaki H., Yamaguchi-Aoki Y., Matsuda T., and Ullrich A. Mutual regulation of protein-tyrosine phosphatase 20 and protein-tyrosine kinase Tec activities by tyrosine phosphorylation and dephosphorylation. J. Biol. Chem. 279 (2004) 10765-10775
3. Babaei-Jadidi R., Karachalias N., Ahmed N., Battah S., and Thornalley P.J. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52 (2003) 2110-2120
4. Bae S.W., Kim H.S., Cha Y.N., Park Y.S., Jo S.A., and Jo I. Rapid increase in endothelial nitric oxide production by bradykinin is mediated by protein kinase A signaling pathway. Biochem. Biophys. Res. Commun. 306 (2003) 981-987
5. Balakumar P., and Singh M. Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats. Pharmacology 78 (2006) 91-97
6. Balakumar P., and Singh M. Possible role of poly (ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy. Methods Find Exp. Clin. Pharmacol. 28 (2006) 683-689
7. Balakumar P., and Singh M. Effect of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase in experimental cardiac hypertrophy. Int. J. Pharmacol. 2 (2006) 543-548
8. Balakumar P., Jindal S., Shah D.I., and Singh M. Experimental models for vascular endothelial dysfunction. Trends Med. Res. 2 (2007) 12-20
9. Balakumar P., Jindal S., and Singh M. Novel use of uric acid and sodium arsenite to induce vascular endothelial dysfunction in rats. J. Pharmacol. Toxicol. 2 (2007) 437-446
10. Balakumar P., Rose M., Ganti S.S., Krishan P., and Singh M. PPAR dual agonists: are they opening Pandora's Box?. Pharmacol. Res. 56 (2007) 91-98
11. Balakumar P., Rose M., and Singh M. Peroxisome proliferator activated receptor agonists: emerging therapy for cardiovascular complications. J. Pharmacol. Toxicol. 2 (2007) 205-219
12. Balakumar P., Rose M., and Singh M. Effect of fenofibrate in pressure overload-induced experimental cardiac hypertrophy. Int. J. Biol. Chem. 1 (2007) 104-110
13. Balakumar P., Rose M., and Singh M. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. Pharmacology 80 (2007) 177-184
14. Balakumar P., Rose M., and Singh M. PPAR ligands. Are they potential agents for cardiovascular disorders?. Pharmacology 80 (2007) 1-10
15. Banes A.K., Shaw S.M., Tawfik A., Patel B.P., Ogbi S., Fulton D., and Marrero M.B. Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin. Am. J. Physiol. Cell Physiol. 288 (2005) C805-C812
16. Banes-Berceli A.K., Ogobi S., Tawfik A., Patel B., Shirley A., Pollock D.M., Fulton D., and Marrero M.B. Endothelin-1 activation of JAK2 in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species. Vascul. Pharmacol. 43 (2005) 310-319
17. Barish G.D., Narkar V.A., and Evans R.M. PPAR delta. A dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116 (2006) 590-597
18. Barter P.J., and Kastelein J.J. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J. Am. Coll. Cardiol. 47 (2006) 492-499
19. Bauer P.M., Yu J., Chen Y., Hickey R., Bernatchez P.N., Looft-Wilson R., Huang Y., Giordano F., Stan R.V., and Sessa W.C. Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 204-209
20. Beckles D.L., Mascareno E., and Siddiqui M.A. Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vascul. Pharmacol. 45 (2006) 350-357
21. Beltramo E., Berrone E., Buttiglieri S., and Porta M. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab. Res. Rev. 20 (2004) 330-336
22. Berrone E., Beltramo E., Solimine C., Ape A.U., and Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J. Biol. Chem. 281 (2006) 9307-9313
23. Boo Y.C., and Jo H. Flow-dependent regulation of endothelial nitric oxide synthase: role of protein kinases. Am. J. Physiol. Cell. Physiol. 285 (2003) C499-C508
24. Boota A., Johnson B., Lee L., Blaskovich M.A., Liu S.X., Kagan V.E., Hamilton A., Pitt B., Sebti S.M., and Davies P. Prenyltransferase inhibitors block superoxide production by pulmonary vascular smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 278 (2000) L329-L334
25. Booz G.W., Day J.N., and Baker K.M. Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J. Mol. Cell. Cardiol. 34 (2002) 1443-1453
26. Bornfeldt K.E., and Krebs E.G. Crosstalk between protein kinase A and growth factor receptor signaling pathways in arterial smooth muscle. Cell. Signal. 11 (1999) 465-477
27. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., Mancuso J.P., and Rader D.J. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350 (2004) 1505-1515
28. Brown J.H., Del Re D.P., and Sussman M.A. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ. Res. 98 (2006) 730-742
29. Bucci M., Gratton J.P., Rudic R.D., Acevedo L., Roviezzo F., Cirino G., and Sessa W.C. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat. Med. 6 (2000) 1362-1367
30. Bucci M., Roviezzo F., Brancaleone V.L., Di Lorenzo A., Cicala C., Pinto A., Sessa W.C., Farneti S., Fiorucci S., and Cirino G. Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 721-726
31. Budzyn K., Marley P.D., and Sobey C.G. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol. Sci. 27 (2006) 97-104
32. Bunderson M., Brooks D.M., Walker D.L., Rosenfeld M.E., Coffin J.D., and Beall H.D. Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicol. Appl. Pharmacol. 201 (2004) 32-39
33. Szabó C., Zanchi A., Komjáti K., Pacher P., Krolewski A.S., Quist W.C., LoGerfo F.W., Horton E.S., and Veves A. Poly (ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106 (2002) 2680-2686
34. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87 (2000) 840-844
35. Cai M., Yin W., Li Q., Liao D., Tsutsumi K., Hou H., Liu Y., Zhang C., Li J., Wang Z., and Xiao J. Effects of NO-1886 on inflammation-associated cytokines in high-fat/high-sucrose/high-cholesterol diet-fed miniature pigs. Eur. J. Pharmacol. 540 (2006) 139-146
36. Cameron N.E., Gibson T.M., Nangle M.R., and Cotter M.A. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann. N.Y. Acad. Sci. 1043 (2005) 784-792
37. Campbell W.B., Falck J.R., and Gauthier K. Role of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factor in bovine coronary arteries. Med. Sci. Monit. 7 (2001) 578-584
38. Carey R.M., and Siragy H.M. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev. 24 (2003) 261-271
39. Carr A.N., Davis M.G., Eby-Wilkens E., Howard B.W., Towne B.A., Dufresne T.E., and Peters K.G. Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H268-H276
40. Catarzi S., Giannoni E., Favilli F., Meacci E., Iantomasi T., and Vincenzini M.T. Sphingosine 1-phosphate stimulation of NADPH oxidase activity: relationship with platelet-derived growth factor receptor and c-Src kinase. Biochim. Biophys. Acta 1770 (2007) 872-883
41. Ceylan-Isik A.F., Wu S., Li Q., Li S.Y., and Ren J. High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J. Appl. Physiol. 100 (2006) 150-156
42. Chellan P., and Nagraj R.H. Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. Arch. Biochem. Biophys. 368 (1999) 98-104
43. Chen W.L., Harris D.L., and Joyce N.C. Effects of SOV-induced phosphatase inhibition and expression of protein tyrosine phosphatases in rat corneal endothelial cells. Exp. Eye Res. 81 (2005) 570-580
44. Chen J., and Ostenson C.G. Inhibition of protein-tyrosine phosphatases stimulates insulin secretion in pancreatic islets of diabetic Goto-Kakizaki rats. Pancreas 30 (2005) 314-317
45. Clark R.W., and Brousseau M.E. Cholesteryl ester transfer protein inhibition and treatment of metabolic syndrome. Drug Discov. Today: Ther. Strat. 2 (2005) 117-124
46. Clements R.T., Minnear F.L., Singer H.A., Keller R.S., and Vincent P.A. RhoA and Rho-kinase dependent and independent signals mediate TGF-beta-induced pulmonary endothelial cytoskeletal reorganization and permeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 288 (2005) L294-L306
47. Culman J., Zhao Y., Gohlke P., and Herdegen T. PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol. Sci. 28 (2007) 244-249
48. Davignon J., and Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109 (2004) III27-III32
49. Davis B.B., Morisseau C., Newman J.W., Pedersen T.L., Hammock B.D., and Weiss R.H. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. J. Pharmacol. Exp. Ther. 316 (2006) 815-821
50. Deem T.L., Abdala-Valencia H., and Cook-Mills J.M. VCAM-1 activation of endothelial cell protein tyrosine phosphatase 1B. J. Immunol. 178 (2007) 3865-3873
51. de Grooth G.J., Klerkx A.H., Stroes E.S., Stalenhoef A.F., Kastelein J.J., and Kuivenhoven J.A. A review of CETP and its relation to atherosclerosis. J. Lipid Res. 45 (2004) 1967-1974
52. Degenhardt T.P., Thorpe S.R., and Baynes J.W. Chemical modification of proteins by methylglyoxal. Cell. Mol. Biol. (Noisy-le-grand) 44 (1998) 1139-1145
53. Desjardins F., and Balligand J.L. Nitric oxide-dependent endothelial function and cardiovascular disease. Acta Clin. Belg. 61 (2006) 326-334
54. Didion S.P., Lynch C.M., and Faraci F.M. Cerebral vascular dysfunction in TallyHo mice: a new model of Type II diabetes. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H1579-H1583
55. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., Rütten H., Fichtlscherer S., Martin H., and Zeiher A.M. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108 (2001) 391-397
56. Doggrell S.A. Inhibitors of cholesteryl ester transfer protein-a new approach to coronary artery disease. Exp. Opin. Invest. Drugs 15 (2006) 99-106
57. Dunford J.E., Rogers M.J., Ebetino F.H., Phipps R.J., and Coxon F.P. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J. Bone Miner. Res. 21 (2006) 684-694
58. Fang X., Kaduce T.L., Weintraub N.L., Harmon S., Teesch L.M., Morisseau C., Thompson D.A., Hammock B.D., and Spector A.A. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J. Biol. Chem. 276 (2001) 14867-14874
59. Fang X., Hu S., Watanabe T., Weintraub N.L., Snyder G.D., Yao J., Liu Y., Shyy J.Y., Hammock B.D., and Spector A.A. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J. Pharmacol. Exp. Ther. 314 (2005) 260-270
60. Ferreira A.J., and Santos R.A. Cardiovascular actions of angiotensin-(1-7). Braz. J. Med. Biol. Res. 38 (2005) 499-507
61. Filippa N., Sable C.L., Filloux C., Hemmings B., and Van Obberghen E. Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Mol. Cell. Biol. 19 (1999) 4989-5000
62. Fleming I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol. Res. 49 (2004) 525-533
63. Fleming I. DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation. Trends Pharmacol. Sci. 28 (2007) 448-452
64. Fleming I., and Busse R. Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension 47 (2006) 629-633
65. Formigli L., Meacci E., Sassoli C., Chellini F., Giannini R., Quercioli F., Tiribilli B., Squecco R., Bruni P., Francini F., and Zecchi-Orlandini S. Sphingosine 1-phosphate induces cytoskeletal reorganization in C2C12 myoblasts: physiological relevance for stress fibres in the modulation of ion current through stretch-activated channels. J. Cell. Sci. 118 (2005) 1161-1171
66. Frank P.G., Woodman S.E., Park D.S., and Lisanti M.P. Caveolin, caveolae, and endothelial cell function. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1161-1168
67. Fritz G., and Kaina B. Rho GTPases: promising cellular targets for novel anticancer drugs. Curr. Cancer Drug Targets 6 (2006) 1-14
68. Fukumoto Y., Tawara S., and Shimokawa H. Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors. Tohoku J. Exp. Med. 211 (2007) 309-320
69. Szabó G., Bährle S., Stumpf N., Sonnenberg K., Szabó E.E., Pacher P., Csont T., Schulz R., Dengler T.J., Liaudet L., Jagtap P.G., Southan G.J., Vahl C.F., Hagl S., and Szabó C. Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ. Res. 90 (2002) 100-106
70. Gadau S., Emanueli C., Van Linthout S., Graiani G., Todaro M., Meloni M., Campesi I., Invernici G., Spillmann F., Ward K., and Madeddu P. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 49 (2006) 405-420
71. Game B.A., He L., Jarido V., Nareika A., Jaffa A.A., Lopes-Virella M.F., and Huang Y. Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice. Atherosclerosis 192 (2007) 85-91
72. Gao T., Furnari F., and Newton A.C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell. 18 (2005) 13-24
73. Garcia-Palmieri M.R. The endothelium in health and in cardiovascular disease. P R Health Sci. J. 16 (1997) 136-141
74. Gervois P., Fruchart J.C., and Staels B. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 145-156
75. Goncalves de Moraes V.L., Singer M., Vargaftig B.B., and Chignard M. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. Br. J. Pharmacol. 123 (1998) 631-636
76. Gottardello Zecchin H., De Souza C.T., Oliveira Prada P., Campello Carvalheira J.B., Augusto Velloso L., and Abdalla Saad M.J. Effect of obesity on insulin signaling through JAK2 in rat aorta. Vascul. Pharmacol. 43 (2005) 346-352
77. Graham T.L., Mookherjee C., Suckling K.E., Palmer C.N., and Patel L. The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis 181 (2005) 29-37
78. Gratton J.P., Bernatchez P., and Sessa W.C. Caveolae and caveolins in the cardiovascular system. Circ. Res. 94 (2004) 1408-1417
79. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., Lin J., Bierhaus A., Nawroth P., Hannak D., Neumaier M., Bergfeld R., Giardino I., and Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 9 (2003) 294-299
80. Hanada M., Feng J., and Hemmings B.A. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim. Biophys. Acta 1697 (2004) 3-16
81. Hara T., Kusunoki M., Tsutsumi K., Okada K., Sakamoto S., Ohnaka M., Nakamura T., Miyata T., Nakayama K., Fukatsu A., Kato K., Kakumu S., and Nakaya Y. A lipoprotein lipase activator, NO-1886, improves endothelium-dependent relaxation of rat aorta associated with aging. Eur. J. Pharmacol. 350 (1998) 75-79
82. Hardin C.D., and Vallejo J. Caveolins in vascular smooth muscle: form organizing function. Cardiovasc. Res. 69 (2006) 808-815
83. Harrington E.O., Smeglin A., Parks N., Newton J., and Rounds S. Adenosine induces endothelial apoptosis by activating protein tyrosine phosphatase: a possible role of p38alpha. Am. J. Physiol. Lung Cell. Mol. Physiol. 279 (2000) L733-L742
84. Herceg Z., and Wang Z.Q. Functions of poly (ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat. Res. 477 (2001) 97-110
85. Hiroki J., Shimokawa H., Higashi M., Morikawa K., Kandabashi T., Kawamura N., Kubota T., Ichiki T., Amano M., Kaibuchi K., and Takeshita A. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J. Mol. Cell. Cardiol. 37 (2004) 537-546
86. Hong S.J., Dawson T.M., and Dawson V.L. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol. Sci. 25 (2004) 259-264
87. Husain K., Vazquez-Ortiz M., and Lalla J. Down regulation of aortic nitric oxide and antioxidant systems in chronic alcohol-induced hypertension in rats. Hum. Exp. Toxicol. 53 (2007) 32-37
88. Iaccarino G., Ciccarelli M., Sorriento D., Cipolletta E., Cerullo V., Iovino G.L., Paudice A., Elia A., Santulli G., Campanile A., Arcucci O., Pastore L., Salvatore F., Condorelli G., and Trimarco B. AKT participates in endothelial dysfunction in hypertension. Circulation 109 (2004) 2587-2593
89. Igarashi J., and Michel T. Agonist-modulated targeting of the EDG-1 receptor to plasmalemmal caveolae. eNOS activation by sphingosine 1-phosphate and the role of caveolin-1 in sphingolipid signal transduction. J. Biol. Chem. 275 (2000) 32363-32370
90. Igarashi J., and Michel T. Sphingosine 1-phosphate and isoform-specific activation of phoshoinositide 3-kinase β. J. Biol. Chem. 276 (2001) 36281-36288
91. Ignarro L.J. Wei Lun Visiting Professorial Lecture: Nitric oxide in the regulation of vascular function: an historical overview. J. Card. Surg. 17 (2002) 301-306
92. Imig J.D. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc. Drug Rev. 24 (2006) 169-188
93. Inceoglu B., Schmelzer K.R., Morisseau C., Jinks S.L., and Hammock B.D. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat. 82 (2007) 42-49
94. Irie K., Fujii E., Ishida H., Wada K., Suganuma T., Nishikori T., Yoshioka T., and Muraki T. Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)-induced microvascular permeability change in mouse skin. Br. J. Pharmacol. 133 (2001) 237-242
95. Javiya V.A., and Patel J.A. The role of peroxisome proliferator-activated receptors in human disease. Indian J. Pharmacol. 38 (2006) 243-253
96. Jiang J.G., Chen R.J., Xiao B., Yang S., Wang J.N., Wang Y., Cowart L.A., Xiao X., Wang D.W., and Xia Y. Regulation of endothelial nitric-oxide synthase activity through phosphorylation in response to epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat. 82 (2007) 162-174
97. Jindal, S., Singh, M., Balakumar, P. Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int. J. Cardiol. doi:10.1016/j.ijcard.2007.05.031, in press.
98. Kanda Y., and Watanabe Y. Adrenaline increases glucose transport via a Rap1-p38MAPK pathway in rat vascular smooth muscle cells. Br. J. Pharmacol. 151 (2007) 476-482
99. Karachalias N., Babaei-Jadid R., Ahmed N., and Thornalley P.J. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem. Soc. Trans. 31 (2003) 1423-1425
100. Karachalias N., Babaei-Jadidi R., Kupich C., Ahmed N., and Thornalley P.J. High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Ann. N.Y. Acad. Sci. 1043 (2005) 777-783
101. Kashyap V.S., Reil T.D., Moore W.S., Hoang T.X., Gelabert H.A., Byrns R.E., Ignarro L.J., and Freischlag J.A. Acute arterial thrombosis causes endothelial dysfunction: a new paradigm for thrombolytic therapy. J. Vasc. Surg. 34 (2001) 323-329
102. Kawashima S., and Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 998-1005
103. Keidar S., Kaplan M., and Gamliel-Lazarovich A. ACE2 of the heart: from angiotensin I to angiotensin (1-7). Cardiovasc. Res. 73 (2007) 463-469
104. Keul P., Tolle M., Lucke S., von Wnuck Lipinski K., Heusch G., Schuchardt M., van der Giet M., and Levkau B. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 607-613
105. Khwaja A., Sharpe C.C., Noor M., and Hendry B.M. The role of geranylgeranylated proteins in human mesangial cell proliferation. Kidney Int. 70 (2006) 1296-1304
106. Kiss L., Chen M., Gero D., Modis K., Lacza Z., and Szabo C. Effects of 7-ketocholesterol on the activity of endothelial poly (ADP-ribose) polymerase and on endothelium-dependent relaxant function. Int. J. Mol. Med. 18 (2006) 1113-1117
107. Klerkx A.H., El Harchaoui K., van der Steeg W.A., Boekholdt S.M., Stroes E.S., Kastelein J.J., and Kuivenhoven J.A. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 706-715
108. Kulhanek-Heinze S., Gerbes A.L., Gerwig T., Vollmar A.M., and Kiemer A.K. Protein kinase A dependent signalling mediates anti-apoptotic effects of the atrial natriuretic peptide in ischemic livers. J. Hepatol. 41 (2004) 414-420
109. Kumar R., Singh V.P., and Baker K.M. Kinase inhibitors for cardiovascular disease. J. Mol. Cell. Cardiol. 42 (2007) 1-11
110. Kusunoki M., Tsutsumi K., Hara T., Ogawa H., Nakamura T., Miyata T., Sakakibara F., Fukuzawa Y., Suga T., Kakumu S., and Nakaya Y. Correlation between lipid and glycogen contents in liver and insulin resistance in high-fat-fed rats treated with the lipoprotein lipase activator NO-1886. Metabolism 51 (2002) 792-795
111. Larsen B.T., Gutterman D.D., and Hatoum O.A. Emerging role of epoxyeicosatrienoic acids in coronary vascular function. Eur. J. Clin. Invest. 36 (2006) 293-300
112. Lee M.J., Thangada S., Paik J.H., Sapkota G.P., Ancellin N., Chae S.S., Wu M., Morales-Ruiz M., Sessa W.C., Alessi D.R., and Hla T. Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol. Cell. 8 (2001) 693-704
113. Lee P.C., Ho I.C., and Lee T.C. Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicol. Sci. 85 (2005) 541-550
114. Leemhuis J., Boutillier S., Schmidt G., and Meyer D.K. The protein kinase A inhibitor H89 acts on cell morphology by inhibiting Rho kinase. J. Pharmacol. Exp. Ther. 300 (2002) 1000-1007
115. Le Goff W., Guerin M., and Chapman M.J. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol. Ther. 101 (2004) 17-38
116. Li Z., Nakaya Y., Niwa Y., and Chen X. K(Ca) channel-opening activity of Ginkgo biloba extracts and ginsenosides in cultured endothelial cells. Clin. Exp. Pharmacol. Physiol. 28 (2001) 441-445
117. Li F.H., Xia W., Li A.W., Zhao C.F., and Sun R.P. Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats. Chin. Med. J. (Engl.) 120 (2007) 22-29
118. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am. J. Cardiol. 96 (2005) 24F-33F
119. Liu Q., Huang Y., and Lu L.M. Effects of ACE2-Ang 1-7-Mas axis on blood vessel. Sheng Li Ke Xue Jin Zhan 38 (2007) 43-48
120. Lohn M., Steioff K., Bleich M., Busch A.E., and Ivashchenko Y. Inhibition of Rho-kinase stimulates nitric oxide-independent vasorelaxation. Eur. J. Pharmacol. 507 (2005) 179-186
121. Luscher T.F., and Barton M. Biology of the endothelium. Clin. Cardiol. 20 (1997) II-3-10
122. Madamanchi N.R., Li S., Patterson C., and Runge M.S. Reactive oxygen species regulate heat-shock protein 70 via the JAK/STAT pathway. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 321-326
123. Malecka S.A., Poprawski K., and Bilski B. Prophylactic and therapeutic application of thiamine (vitamin B1)-a new point of view. Wiad Lek. 59 (2006) 383-387
124. McCarter S.D., Lai P.F., Suen R.S., and Stewart D.J. Regulation of endothelin-1 by angiopoietin-1: implications for inflammation. Exp. Biol. Med. (Maywood) 231 (2006) 985-991
125. Mangoni A.A., Sherwood R.A., Asonganyi B., Ouldred E.L., Thomas S., and Jackson S.H. Folic acid: a marker of endothelial function in type 2 diabetes?. Vasc. Health Risk Manage. 1 (2005) 79-83
126. Mascareno E., El-Shafei M., Maulik N., Sato M., Guo Y., Das D.K., and Siddiqui M.A. JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation 104 (2001) 325-329
127. Marrero M.B., Banes-Berceli A.K., Stern D.M., and Eaton D.C. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 290 (2006) F762-F768
128. Marx N., Sukhova G.K., Collins T., Libby P., and Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 (1999) 3125-3131
129. Mayhan W.G., and Sharpe G.M. Chronic exposure to nicotine alters endothelium-dependent arteriolar dilatation: effect of superoxide dismutase. J. Appl. Physiol. 86 (1999) 1126-1134
130. McKenney J.M., Davidson M.H., Shear C.L., and Revkin J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J. Am. Coll. Cardiol. 48 (2006) 1782-1790
131. Mc Verry B.J., and Garcia J.G.N. In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cell. Signal. 17 (2005) 131-139
132. Morales-Ruiz M., Lee M.J., Zollner S., Gratton J.P., Scotland R., Shiojima I., Walsh K., Hla T., and Sessa W.C. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J. Biol. Chem. 276 (2001) 19672-19677
133. Morikawa-Futamatsu K., Adachi S., Maejima Y., Tamamori-Adachi M., Suzuki J., Kitajima S., Ito H., and Isobe M. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sci. 79 (2006) 1380-1390
134. Morton R.E., and Greene D.J. Partial suppression of CETP activity beneficially modifies the lipid transfer profile of plasma. Atherosclerosis 192 (2007) 100-107
135. Nakamura A., Harada N., Takahashi A., Mawatari K., Nakano M., Tsutsumi K., and Nakaya Y. NO-1886, a lipoprotein lipase activator, attenuates vascular smooth muscle contraction in rat aorta. Eur. J. Pharmacol. 554 (2007) 183-190
136. Naseem K.M. The role of nitric oxide in cardiovascular diseases. Mol. Asp. Med. 26 (2005) 33-65
137. Neunteufl T., Priglinger U., Heher S., Zehetgruber M., Söregi G., Lehr S., Huber K., Maurer G., Weidinger F., and Kostner K. Effects of vitamin E on chronic and acute endothelial dysfunction in smokers. J. Am. Coll. Cardiol. 35 (2000) 277-283
138. Newaz M., Blanton A., Fidelis P., and Oyekan A. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects. Mutat. Res. 579 (2005) 163-171
139. Nishimura J., Bi D., and Kanaide H. Dependence of proliferating dedifferentiated vascular smooth muscle contraction on Rho-Rho kinase system. Trends Cardiovasc. Med. 16 (2006) 124-128
140. Nodai A., Machida T., Izumi S., Hamaya Y., Kohno T., Igarashi Y., Iizuka K., Minami M., and Hirafuji M. Sphingosine 1-phosphate induces cyclooxygenase-2 via Ca2+-dependent, but MAPK-independent mechanism in rat vascular smooth muscle cells. Life Sci. 80 (2007) 1768-1776
141. Nofer J.R., Bot M., Brodde M., Taylor P.J., Salm P., Brinkmann V., van Berkel T., Assmann G., and Biessen E.A. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 115 (2007) 501-508
142. Nohria A., Grunert M.E., Rikitake Y., Noma K., Prsic A., Ganz P., Liao J.K., and Creager M.A. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ. Res. 99 (2006) 1426-1432
143. Okano J., Gaslightwala I., Birnbaum M.J., Rustgi A.K., and Nakagawa H. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J. Biol. Chem. 275 (2000) 30934-30942
144. Pacher P., Liaudet L., Soriano F.G., Mabley J.G., Szabó E., and Szabó C. The role of poly (ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51 (2002) 514-521
145. Pacher P., Mabley J.G., Soriano F.G., Liaudet L., Komjati K., and Szabo C. Endothelial dysfunction in aging animals: the role of poly (ADP-ribose) polymerase activation. Br. J. Pharmacol. 135 (2002) 1347-1350
146. Pacher P., Vaslin A., Benko R., Mabley J.G., Liaudet L., Haskó G., Marton A., Bátkai S., Kollai M., and Szabó C. A new, potent poly (ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging. J. Pharmacol. Exp. Ther. 311 (2004) 485-491
147. Pacher P., and Szabó C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid. Redox Signal. 7 (2005) 1568-1580
148. Pacher P., Liaudet L., Mabley J.G., Cziráki A., Haskó G., and Szabó C. Beneficial effects of a novel ultrapotent poly (ADP-ribose) polymerase inhibitor in murine models of heart failure. Int. J. Mol. Med. 17 (2006) 369-375
149. Pacher P., and Szabó C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc. Drug Rev. 25 (2007) 235-260
150. Papaharalambus C.A., and Griendling K.K. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc. Med. 17 (2007) 48-54
151. Patil S., Bunderson M., and Wilham J. Black SM. Important role for Rac1 in regulating reactive oxygen species generation and pulmonary arterial smooth muscle cell growth. Am. J. Physiol. Lung Cell. Mol. Physiol. 287 (2004) LI10
152. Pesic S., Radenkovic M., and Grbovic L. Endothelial dysfunction: mechanisms of development and therapeutic options. Med. Pregl. 59 (2006) 335-341
153. Peters S.L.M., and Alewijnse A.E. Sphingosine-1-phosphate signaling in the cardiovascular system. Curr. Opin. Pharmacol. 7 (2007) 1-7
154. Pomero F., Molinar Min A., La Selva M., Allione A., Molinatti G.M., and Porta M. Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetol. 38 (2001) 135-138
155. Puddu P., Puddu G.M., and Muscari A. Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression?. Int. J. Cardiol. 90 (2003) 133-140
156. Qiao J., Huang F., and Lum H. PKA inhibits RhoA activation: a protection mechanism against endothelial barrier dysfunction. Am. J. Physiol. Lung Cell. Mol. Physiol. 284 (2003) L972-L980
157. Razani B., Woodman S.E., and Lisanti M.P. Caveolae: from cell biology to animal physiology. Pharmacol. Rev. 54 (2002) 431-467
158. Recinos A., 3rd, Lejeune W.S., Sun H., Lee C.Y., Tieu B.C., Lu M., Hou T., Boldogh I., Tilton R.G., and Brasier A.R. Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis 194 (2007) 125-133
159. Rikitake Y., Kim H.H., Huang Z., Seto M., Yano K., Asano T., Moskowitz M.A., and Liao J.K. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36 (2005) 2251-2257
160. Rush J.W., Denniss S.G., and Graham D.A. Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity. Can. J. Appl. Physiol. 30 (2005) 442-474
161. Saijonmaa O., Nyman T., and Fyhrquist F. Regulation of angiotensin-converting enzyme production by nicotine in human endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H2000-H2004
162. Sampaio W.O., Souza dos Santos R.A., Faria-Silva R., da Mata Machado L.T., Schiffrin E.L., and Touyz R.M. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49 (2007) 185-192
163. Sanchez-Ramirez G.M., Caram-Salas N.L., Rocha-Gonzalez H.I., Vidal-Cantú G.C., Medina-Santillán R., Reyes-García G., and Granados-Soto V. Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur. J. Pharmacol. 530 (2006) 48-53
164. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., Heringer-Walther S., Pinheiro S.V., Lopes M.T., Bader M., Mendes E.P., Lemos V.S., Campagnole-Santos M.J., Schultheiss H.P., Speth R., and Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 8258-8263
165. Santos R.A., Frezard F., and Ferreira A.J. Angiotensin-(1-7): blood, heart, and blood vessels. Curr. Med. Chem. Cardiovasc. Hematol. Agents 3 (2005) 383-391
166. Sareila O., Korhonen R., Karpanniemi O., Nieminen R., Kankaanranta H., and Moilanen E. JAK inhibitors AG-490 and WHI-P154 decrease IFN-gamma-induced iNOS expression and NO production in macrophages. Mediat. Inflamm. 2006 (2006) 16161
167. Savoia C., and Schiffrin E.L. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin. Sci. (Lond.) 112 (2007) 375-384
168. Schubert W., Frank P.G., Woodman S.E., Hyogo H., Cohen D.E., Chow C.W., and Lisanti M.P. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J. Biol. Chem. 277 (2002) 40091-40098
169. Schubert R. Sphingosine-1-phosphate in the circulatory system: cause and therapeutic target for vascular dysfunction?. Cardiovasc. Res. 70 (2006) 9-11
170. Schwencke C., Schmeisser A., Walter C., Wachter R., Pannach S., Weck B., Braun-Dullaeus R.C., Kasper M., and Strasser R.H. Decreased caveolin-1 in atheroma: loss of antiproliferative control of vascular smooth muscle cells in atherosclerosis. Cardiovasc. Res. 68 (2005) 128-135
171. Sedding D.G., and Braun-Dullaeus R.C. Caveolin-1: dual role for proliferation of vascular smooth muscle cells. Trends Cardiovasc. Med. 1 (2006) 50-55
172. Sessa W.C. Regulation of endothelial derived nitric oxide in health and disease. Mem. Inst. Oswaldo. Cruz. 100 (2005) 15-18
173. Shah D.I., and Singh M. Involvement of Rho-kinase in experimental vascular endothelial dysfunction. Mol. Cell. Biochem. 283 (2006) 191-199
174. Shah D.I., and Singh M. Effect of fasudil on macrovascular disorder-induced endothelial dysfunction. Can. J. Physiol. Pharmacol. 84 (2006) 835-845
175. Shah D.I., and Singh M. Effect of bis(maltolato) oxovanadium on experimental vascular endothelial dysfunction. Naunyn Schmiedebergs Arch. Pharmacol. 373 (2006) 221-229
176. Shah D.I., and Singh M. Inhibition of protein tyrosin phosphatase improves vascular endothelial dysfunction. Vascul. Pharmacol. 44 (2006) 177-182
177. Shah D.I., and Singh M. Possible role of exogenous cAMP to improve vascular endothelial dysfunction in hypertensive rats. Fundam. Clin. Pharmacol. 20 (2006) 595-604
178. Shah D.I., and Singh M. Activation of protein kinase A improves vascular endothelial dysfunction. Endothelium 13 (2006) 267-277
179. Shah D.I., and Singh M. Effect of demethylasterriquinone b1 in hypertension associated vascular endothelial dysfunction. Int. J. Cardiol. 120 (2007) 317-324
180. Shah D.I., and Singh M. Possible role of Akt to improve vascular endothelial dysfunction in diabetic and hyperhomocysteinemic rats. Mol. Cell. Biochem. 295 (2007) 65-74
181. Shimokawa H., and Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1767-1775
182. Shiojima I., and Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 90 (2002) 1243-1250
183. Sidhu J.S., and Kaski J.C. Peroxisome proliferator-activated receptor gamma: a potential target in the management of ischaemic heart disease. Heart 86 (2001) 255-258
184. Spector A.A., Fang X., Snyder G.D., and Weintraub N.L. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. 43 (2004) 55-90
185. Sood H.S., Hunt M.J., and Tyagi S.C. Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia. Am. J. Physiol. Lung Cell. Mol. Physiol. 284 (2003) L333-L341
186. Soriano F.G., Virag L., and Szabo C. Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly (ADP-ribose) polymerase activation. J. Mol. Med. 79 (2001) 437-448
187. Staels B., Koenig W., and Habib A. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393 (1998) 790-793
188. Stankevicius E., Kevelaitis E., Vainorius E., and Simonsen U. Role of nitric oxide and other endothelium-derived factors. Medicina (Kaunas) 39 (2003) 333-341
189. Sugano M., Tsuchida K., and Makino N. A protein tyrosine phosphatase inhibitor accelerates angiogenesis in a rat model of hindlimb ischemia. J. Cardiovasc. Pharmacol. 44 (2004) 460-465
190. Sullivan G.W., Rieger J.M., Scheld W.M., Macdonald T.L., and Linden J. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. Br. J. Pharmacol. 132 (2001) 1017-1026
191. Szabo C., Cuzzocrea S., Zingarelli B., O'Connor M., and Salzman A.L. Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J. Clin. Invest. 100 (1997) 723-735
192. Szabo C. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect. 15 (2002) 197-205
193. Szabo C., Pacher P., Zsengellér Z., Vaslin A., Komjáti K., Benkö R., Chen M., Mabley J.G., and Kollai M. Angiotensin II-mediated endothelial dysfunction: role of poly (ADP-ribose) polymerase activation. Mol. Med. 10 (2004) 28-35
194. Takahashi S., Tanaka T., Kodama T., and Sakai J. Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome. Pharmacol. Res. 53 (2006) 501-507
195. Tanaka K., Kawano T., Nakamura A., Nazari H., Kawahito S., Oshita S., Takahashi A., and Nakaya Y. Isoflurane activates sarcolemmal adenosine triphosphate-sensitive potassium channels in vascular smooth muscle cells: a role for protein kinase A. Anesthesiology 106 (2007) 984-991
196. Taniyama Y., and Griendling K.K. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42 (2003) 1075-1081
197. Tasatargil A., Dalaklioglu S., and Sadan G. Poly (ADP-ribose) polymerase inhibition prevents homocysteine-induced endothelial dysfunction in the isolated rat aorta. Pharmacology 72 (2004) 99-105
198. Tasatargil A., Sadan G., and Karasu E. Homocysteine-induced changes in vascular reactivity of guinea-pig pulmonary arteries: role of the oxidative stress and poly (ADP-ribose) polymerase activation. Pulm. Pharmacol. Ther. 20 (2007) 265-272
199. Tawara S., and Shimokawa H. Progress of the study of rho-kinase and future perspective of the inhibitor. Yakugaku Zasshi 127 (2007) 501-514
200. Thomas M.C., Baynes J.W., Thorpe S.R., and Cooper M.E. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr. Drug Targets 6 (2005) 453-474
201. Thompson M.M., Reed S.C., and Cockerill G.W. Therapeutic approaches to raising plasma HDL-cholesterol levels. Nat. Clin. Pract. Cardiovasc. Med. 1 (2004) 84-89
202. Tirapelli C.R., Casolari D.A., Montezano A.C., Yogi A., Tostes R.C., Legros E., D'Orléans-Juste P., Lanchote V.L., Uyemura S.A., and de Oliveira A.M. Ethanol consumption enhances endothelin-1-induced contraction in the isolated rat carotid. J. Pharmacol. Exp. Ther. 318 (2006) 819-827
203. Touyz R.M., and Schiffrin E.L. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul. Pharmacol. 45 (2006) 19-28
204. Tsai S.H., Hsieh M.S., Chen L., Liang Y.C., Lin J.K., and Lin S.Y. Suppression of Fas ligand expression on endothelial cells by arsenite through reactive oxygen species. Toxicol. Lett. 123 (2001) 11-19
205. Tsou T.C., Tsai F.Y., Hsieh Y.W., Li L.A., Yeh S.C., and Chang L.W. Arsenite induces endothelial cytotoxicity by down-regulation of vascular endothelial nitric oxide synthase. Toxicol. Appl. Pharmacol. 208 (2005) 277-284
206. Tsutsumi K. Lipoprotein lipase and atherosclerosis. Curr. Vascul. Pharmacol. 1 (2003) 11-17
207. Tsygankova O.M., Kupperman E., Wen W., and Meinkoth J.L. Cyclic AMP activates Ras. Oncogene 19 (2000) 3609-3615
208. Ungvári Z., Gupte S.A., Recchia F.A., Bátkai S., and Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr. Vasc. Pharmacol. 3 (2005) 221-229
209. Van der Steeg W.A., El-Harchaoui K., Kuivenhoven J.A., and Kastelein J.J. Increasing high-density lipoprotein cholesterol through cholesteryl ester transfer protein inhibition: a next step in the fight against cardiovascular disease?. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5 (2005) 481-488
210. van Nieuw Amerongen G.P., van Delft S., Vermeer M.A., Collard J.G., and van Hinsbergh V.W. Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases. Circ. Res. 87 (2000) 335-340
211. Vercauteren M., Remy E., Devaux C., Dautreaux B., Henry J.P., Bauer F., Mulder P., Hooft van Huijsduijnen R., Bombrun A., Thuillez C., and Richard V. Improvement of peripheral endothelial dysfunction by protein tyrosine phosphatase inhibitors in heart failure. Circulation 114 (2006) 2498-2507
212. Verma S., and Szmitko P.E. The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis. Can. J. Cardiol. 22 (2006) 12B-7B
213. Watterson K.R., Ratz P.H., and Spiegel S. The role of sphingosine-1-phosphate in smooth muscle contraction. Cell. Signal. 17 (2005) 289-298
214. Wei Y., Yang X., Liu Q., Wilkins J.A., and Chapman H.A. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell. Biol. 144 (1999) 1285-1294
215. Weintraub N.L., Fang X., Kaduce T.L., VanRollins M., Chatterjee P., and Spector A.A. Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am. J. Physiol. 277 (1999) H2098-H2108
216. Weir E.K., and Olschewski A. Role of ion channels in acute and chronic responses of the pulmonary vasculature to hypoxia. Cardiovasc. Res. 71 (2006) 630-641
217. Williams T.M., and Lisanti M.P. The Caveolin genes: from cell biology to medicine. Ann. Med. 36 (2004) 584-595
218. Winaver J., Ovcharenko E., Rubinstein I., Gurbanov K., Pollesello P., Bishara B., Hoffman A., and Abassi Z. Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H2007-H2014
219. Wolfe M.L., and Rader D.J. Cholesteryl ester transfer protein and coronary artery disease: an observation with therapeutic implications. Circulation 110 (2004) 1338-1340
220. Woodman O.L., Missen M.A., and Boujaoude M. Daidzein and 17 beta-estradiol enhance nitric oxide synthase activity associated with an increase in calmodulin and a decrease in caveolin-1. J. Cardiovasc. Pharmacol. 44 (2004) 155-163
221. Wu F., Schuster D.P., Tyml K., and Wilson J.X. Ascorbate inhibits NADPH oxidase subunit p47phox expression in microvascular endothelial cells. Free Radic. Biol. Med. 42 (2007) 124-131
222. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H.J., Kim I.H., Tuteja D., Mateo R.K., Singapuri A., Davis B.B., Low R., Hammock B.D., and Chiamvimonvat N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 18733-18738
223. Yang S., Lin L., and Chen J.X. Cytochrome P450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-{alpha} via MAPK and PI3K/Akt Signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H142-H151
224. Yin W., and Tsutsumi K. Lipoprotein lipase activator NO-1886. Cardiovasc. Drug Rev. 21 (2003) 133-142
225. Yin W., Tsutsumi K., Yuan Z., and Yang B. Effects of the lipoprotein lipase activator NO-1886 as a suppressor agent of atherosclerosis in aorta of mild diabetic rabbits. Arzneimittelforschung 52 (2002) 610-614
226. Yung L.M., Leung F.P., Yao X., Chen Z.Y., and Huang Y. Reactive oxygen species in vascular wall. Cardiovasc. Hematol. Disord. Drug Targets 6 (2006) 1-19
227. Zhang W., Koerner I.P., Noppens R., Grafe M., Tsai H.J., Morisseau C., Luria A., Hammock B.D., Falck J.R., and Alkayed N.J. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J. Cereb. Blood Flow Metab. 27 (2007) 1931-1940
228. Zuckerbraun B.S., Barbato J.E., Hamilton A., Sebti S., and Tzeng E. Inhibition of geranylgeranyltransferase I decreases generation of vascular reactive oxygen species and increases vascular nitric oxide production. J. Surg. Res. 124 (2005) 256-263